Browse All

Current Filters

CLEAR FILTER x

TITLE

Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of ACP-711 (SAN711): A Novel GABAA Subunit a3 Selective Modulator

Author:Amrutkar, Dipak V.   Sandager-Nielsen, Karin   Dyhring, Tino   Jacobsen, Thomas Amos   Larsen, Janus S.   Muglia, Pierandrea   Pathak, Sanjeev   Lin, Hank   Hofbauer, Robert   

Session Name:P8: Movement Disorders: Parkinson's Disease Emerging Therapeutics 2  

Topic:Movement Disorders  

Program Number:P8.012  

Author Institution:Saniona A/S, Glostrup, Denmark  Acadia Pharmaceuticals, Inc., Princeton, NJ  Acadia Pharmaceuticals, Inc., San Diego, CA  

Impact of Baseline Sleep Disturbances on Pimavanserin Response in Parkinson’s Disease Psychosis: A Post Hoc Analysis

Author:Chrones, Lambros   Naujoks, Karla   Zhang, Peter   Feng, Xiaoshu   Brunson, Greg   Krystal, Andrew   

Session Name:P11: Aging, Dementia, and Behavioral Neurology: Synucleinopathies  

Topic:Aging, Dementia, and Behavioral Neurology  

Program Number:P11.007  

Author Institution:Acadia Pharmaceuticals, Inc., Westmont, IL  Acadia Pharmaceuticals, Inc., San Diego, CA  Acadia Pharmaceuticals, Inc., North Potomac, MD  Acadia Pharmaceuticals, Inc., San Clemente, CA  Departments of Psychiatry and Neurology, University of California - San Francisco, San Francisco, CA